ABSTRACT
Objective To explore the effect of Ludangshen Oral Liquid for treatment of convalescent patients with coronavirus disease 2019 (COVID-19) with randomized, double-blind, placebo-controlled multicenter method.Methods200 convalescent COVID-19 patients who had symptoms related to decreased digestive and respiratory function were randomly divided to either receive Ludangshen Oral Liquid or placebo for 2 weeks. The severity of clinical symptoms including fatigue, anorexia, abdominal distension, loose stools, and shortness of breath were assessed by visual analogue scale and observed at before and after treatment. The improvement and resolution rates of clinical symptoms were evaluated. Full analysis set (FAS) and per-protocol set (PPS) were used for statistical analyses. Adverse events were recorded during the study. Results8 patients did not complete the study. After 2 weeks of treatment, both FAS and PPS results showed that patients in Ludangshen group had significantly lower score of fatigue, anorexia, loose stools, and shortness of breath than placebo group (P < 0.05), while there was no significant difference in distention (P > 0.05). The improvement rate of fatigue, anorexia, distension, loose stools and shortness of breath were significantly higher in Ludangshen group (P < 0.05), as well as the resolution rates (P < 0.05) except for shortness of breath (P > 0.05). There were two cases of adverse events, with one nose bleeding in Ludangshen group and one headache in placebo group. ConclusionThe study suggested that two weeks of Ludangshen Oral Liquid treatment may have certain effects for convalescent COVID-19 patients on improving digestive and respiratory symptoms including fatigue, anorexia, loose stools and shortness of breath, which may be one of the choices for management of convalescent COVID-19 patients with digestive and respiratory symptoms.
Subject(s)
COVID-19ABSTRACT
Objectives To investigate the relationship between the dynamic changes of serum 2019-nCoV IgM/IgG and immunity alteration for patients after discharged six months. Methods 1 with IgM(+) and IgG(-), 32 with IgM(+) and IgG(+), 38 with IgM(-) and IgG(+), and 40 with IgM(-) and IgG(-) were included. Demographic data were collected. IgM and IgG antibodies, hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6) and lymphocyte subsets in serum were determined on weeks 0, 2 and 4. Results Hs-CRP and IL-6 for all patients were within the normal ranges. All testing items of the lymphocyte subsets were 12/110 (10.9%) of weeks 0, 15/110 (13.6%) of weeks 2 and 18/110 (16.4%) of weeks 4 within the normal ranges. The percentages of CD8+, NK cells and B lymphocytes in the IgM(+) and IgG(+) group were quite different from the IgM(-) and IgG(+) group and the IgM(-)and IgG(-) group, with much more the percentages of CD8+ and much less the percentages of NK cells and B lymphocytes on weeks 0, 2 and 4. 12 patients with IgM(+) had converted to IgM(-) in the IgM(+) and IgG(+) group, and the percentages of NK cells and B lymphocytes were significantly increased on weeks 4.Conclusions The changes of serum IgM and IgG are closely related to immunity for patients in recovery stage. However, immunity isn't recovery with the turning negative of antibodies.
ABSTRACT
Background Coronavirus disease 2019(COVID-19) is a worldwide pandemic.In this study, we aimed to evaluate the risk factors of death from severe and critical COVID-19 patients.Method A retrospective study of patients diagnosed with severe and critical COVID-19 from four hospitals in Wuhan, China, describing the clinical characteristics and laboratory results, and using Cox regression to study the risk factors was conducted.Results Four hundred and forty-six patients with COVID-19 showed a high case fatality rate(CFR)(20.2%). All patients required oxygen therapy, and 52(12%) patients required invasive mechanical ventilation,of which 50(96%) patients died.The univariate Cox proportional hazard model showed a white blood cell count of more than 10 × 10⁹/L(HR3.903,95%CI 2.413 to 6.313),patients’ risk of death significantly increased.The multivariate Cox proportional hazard model demonstrated that older age (HR 1.074, 95% CI 1.050 to 1.098) was an independent risk factor and high white blood cell count(HR 1.119, 95% CI 1.056 to 1.186)was a predictive factor for COVID-19 on admission.Conclusions COVID-19 is a new disease entity that carries significant risk of morbidity and CFR.Older age was an independent risk factor and high white blood cell was a predictive factor for COVID-19.